JP2018535951A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535951A5 JP2018535951A5 JP2018519352A JP2018519352A JP2018535951A5 JP 2018535951 A5 JP2018535951 A5 JP 2018535951A5 JP 2018519352 A JP2018519352 A JP 2018519352A JP 2018519352 A JP2018519352 A JP 2018519352A JP 2018535951 A5 JP2018535951 A5 JP 2018535951A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- azacitidine
- amount
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 23
- 229960002756 azacitidine Drugs 0.000 claims description 23
- 229940125904 compound 1 Drugs 0.000 claims description 21
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000012650 DNA demethylating agent Substances 0.000 claims description 9
- 229940045805 DNA demethylating agent Drugs 0.000 claims description 9
- 239000002207 metabolite Substances 0.000 claims description 9
- 239000000651 prodrug Substances 0.000 claims description 9
- 229940002612 prodrug Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 108700028369 Alleles Proteins 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 206010066476 Haematological malignancy Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 3
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims description 3
- 102200116484 rs121913502 Human genes 0.000 claims description 3
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 3
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 3
- 238000011260 co-administration Methods 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 239000003112 inhibitor Substances 0.000 description 17
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 3
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 3
- 230000006872 improvement Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242218P | 2015-10-15 | 2015-10-15 | |
| US62/242,218 | 2015-10-15 | ||
| PCT/US2016/057102 WO2017066611A1 (en) | 2015-10-15 | 2016-10-14 | Combination therapy for treating malignancies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535951A JP2018535951A (ja) | 2018-12-06 |
| JP2018535951A5 true JP2018535951A5 (OSRAM) | 2019-11-28 |
| JP6895956B2 JP6895956B2 (ja) | 2021-06-30 |
Family
ID=57219007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519352A Active JP6895956B2 (ja) | 2015-10-15 | 2016-10-14 | 悪性腫瘍を治療するための併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10695352B2 (OSRAM) |
| EP (1) | EP3362070B1 (OSRAM) |
| JP (1) | JP6895956B2 (OSRAM) |
| KR (1) | KR102701893B1 (OSRAM) |
| CN (1) | CN108601787B (OSRAM) |
| AU (1) | AU2016340098B2 (OSRAM) |
| BR (1) | BR112018007447B1 (OSRAM) |
| CA (1) | CA3002029A1 (OSRAM) |
| CL (1) | CL2018000955A1 (OSRAM) |
| EA (1) | EA036129B1 (OSRAM) |
| ES (1) | ES2862730T3 (OSRAM) |
| IL (1) | IL258580B (OSRAM) |
| MX (1) | MX381582B (OSRAM) |
| SG (2) | SG10201912869WA (OSRAM) |
| WO (1) | WO2017066611A1 (OSRAM) |
| ZA (1) | ZA201802420B (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9986928B2 (en) | 2013-12-09 | 2018-06-05 | Medtronic, Inc. | Noninvasive cardiac therapy evaluation |
| CA2942072C (en) | 2014-03-14 | 2022-07-26 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| MA71411A (fr) | 2015-10-15 | 2025-04-30 | Les Laboratoires Servier | Polythérapie pour le traitement de tumeurs malignes |
| DK3362066T3 (da) * | 2015-10-15 | 2021-11-22 | Les Laboratoires Servier Sas | Kombinationsterapi til behandling af maligniteter |
| SG10201912886XA (en) | 2015-10-15 | 2020-02-27 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| US11219769B2 (en) | 2016-02-26 | 2022-01-11 | Medtronic, Inc. | Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing |
| CN109715143A (zh) | 2016-09-07 | 2019-05-03 | 细胞基因公司 | 片剂组合物 |
| ES2968376T3 (es) | 2017-05-05 | 2024-05-09 | Memorial Sloan Kettering Cancer Center | Métodos de tratamiento de neoplasia mieloproliferativa |
| JP7263669B2 (ja) * | 2017-06-12 | 2023-04-25 | レ ラボラトワール セルヴィエ | 併用療法を用いて脳腫瘍を処置する方法 |
| EP3651772A4 (en) * | 2017-07-09 | 2021-04-07 | BioSight Ltd. | ANTI-CANCER POLYTHERAPY |
| US11285312B2 (en) | 2018-03-29 | 2022-03-29 | Medtronic, Inc. | Left ventricular assist device adjustment and evaluation |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| US11697025B2 (en) | 2019-03-29 | 2023-07-11 | Medtronic, Inc. | Cardiac conduction system capture |
| CN113853217A (zh) * | 2019-04-29 | 2021-12-28 | 伊缪诺金公司 | 包含抗cd123免疫缀合物的治疗组合 |
| JP2022537384A (ja) | 2019-06-20 | 2022-08-25 | セルジーン コーポレーション | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| US12201843B2 (en) | 2019-10-09 | 2025-01-21 | Medtronic, Inc. | Synchronizing external electrical activity |
| US11497431B2 (en) | 2019-10-09 | 2022-11-15 | Medtronic, Inc. | Systems and methods for configuring cardiac therapy |
| JP2023503842A (ja) | 2019-11-14 | 2023-02-01 | セルジーン コーポレーション | がんを処置するための小児用製剤 |
| CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
| US20240229156A1 (en) * | 2021-03-12 | 2024-07-11 | Celgene Corporation | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| EP0998271B3 (en) | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| ATE340563T1 (de) | 2000-02-04 | 2006-10-15 | Depomed Inc | DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
| US8846628B2 (en) * | 2008-05-15 | 2014-09-30 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| US8530445B2 (en) * | 2008-06-09 | 2013-09-10 | Cyclacel Limited | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine |
| EP2406389B1 (en) | 2009-03-13 | 2019-05-08 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011050211A2 (en) * | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| JP6231988B2 (ja) * | 2011-11-03 | 2017-11-15 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与 |
| SG11201403878QA (en) | 2012-01-06 | 2014-08-28 | Agios Pharmaceuticals Inc | Therapeutically active compounds and their methods of use |
| NZ715738A (en) * | 2013-07-11 | 2021-06-25 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| WO2016053850A1 (en) | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| KR102628370B1 (ko) | 2015-02-04 | 2024-01-24 | 르 라보레또레 쎄르비에르 | 치료적 활성 화합물 및 이들의 사용 방법 |
| US9751863B2 (en) | 2015-08-05 | 2017-09-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| SG10201912886XA (en) | 2015-10-15 | 2020-02-27 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| MX380596B (es) | 2015-12-04 | 2025-03-12 | Agios Pharmaceuticals Inc | Compuesto para usarse en el tratamiento de neoplasias malignas. |
| EP3419593B1 (en) | 2016-02-26 | 2022-03-23 | Celgene Corporation | Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia |
-
2016
- 2016-10-14 SG SG10201912869WA patent/SG10201912869WA/en unknown
- 2016-10-14 JP JP2018519352A patent/JP6895956B2/ja active Active
- 2016-10-14 EP EP16788866.8A patent/EP3362070B1/en active Active
- 2016-10-14 AU AU2016340098A patent/AU2016340098B2/en active Active
- 2016-10-14 US US15/768,462 patent/US10695352B2/en active Active
- 2016-10-14 SG SG11201802964QA patent/SG11201802964QA/en unknown
- 2016-10-14 MX MX2018004599A patent/MX381582B/es unknown
- 2016-10-14 KR KR1020187013741A patent/KR102701893B1/ko active Active
- 2016-10-14 WO PCT/US2016/057102 patent/WO2017066611A1/en not_active Ceased
- 2016-10-14 BR BR112018007447-0A patent/BR112018007447B1/pt active IP Right Grant
- 2016-10-14 EA EA201890961A patent/EA036129B1/ru not_active IP Right Cessation
- 2016-10-14 CA CA3002029A patent/CA3002029A1/en not_active Abandoned
- 2016-10-14 CN CN201680072973.3A patent/CN108601787B/zh active Active
- 2016-10-14 ES ES16788866T patent/ES2862730T3/es active Active
-
2018
- 2018-04-09 IL IL258580A patent/IL258580B/en active IP Right Grant
- 2018-04-12 ZA ZA2018/02420A patent/ZA201802420B/en unknown
- 2018-04-13 CL CL2018000955A patent/CL2018000955A1/es unknown
-
2020
- 2020-05-21 US US16/880,871 patent/US20210100805A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535951A5 (OSRAM) | ||
| JP2019502669A5 (OSRAM) | ||
| JP2019513694A5 (OSRAM) | ||
| JP2021098740A5 (OSRAM) | ||
| JP2019510746A5 (OSRAM) | ||
| JP2018536636A5 (OSRAM) | ||
| JP2018534288A5 (OSRAM) | ||
| JP2019507721A5 (OSRAM) | ||
| JP2019142930A5 (OSRAM) | ||
| JP2017008088A5 (OSRAM) | ||
| JP2019216716A5 (OSRAM) | ||
| JP2017528487A5 (OSRAM) | ||
| JP2022166014A5 (OSRAM) | ||
| Gerber et al. | Management and future directions in non-small cell lung cancer with known activating mutations | |
| JP2020514311A5 (OSRAM) | ||
| IL278381B2 (en) | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer | |
| IL292608A (en) | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| JP2014513110A5 (OSRAM) | ||
| JP2006501176A5 (OSRAM) | ||
| JP2015508103A5 (OSRAM) | ||
| JP2013518089A5 (OSRAM) | ||
| JP2015511217A5 (OSRAM) | ||
| JP2015529194A5 (OSRAM) | ||
| JP2016503779A5 (OSRAM) | ||
| JP2010502767A5 (OSRAM) |